Introduction {#sec1}
============

In the tabulated list of important functional groups available in any standard organic chemistry tutorial, the amide group would occupy a prominent position, not only as the backbone of proteins but also as an ubiquitous component of unnatural materials.^[@ref1]^ Historically, amides have been prepared from carboxylic acids and amines, especially via activation of carboxylic acids in the presence of a coupling agent.^[@ref2]^ An α-functionalized carboxylic acid may exert dissimilar reactivity toward amidation, which often could remain unnoticed ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref3]^ Amide formation from arylglyoxylic acids containing an electron-withdrawing α-carbonyl functionality has been in line with the victory. The arylglyoxylic amides represent a key structural unit of many natural compounds and pharmaceuticals displaying a broad spectrum of biological activities.^[@ref4]^ Among the various methods to prepare them,^[@ref2]^ the most privileged method involves condensation of arylglyoxylic acids and amines using commonly used coupling agents.^[@ref5]^ However, amide formation directly from arylglyoxylic acid and amines often causes impediment,^[@ref6]^ as amines could undergo condensation with arylglyoxylic acids to form α-imino carboxylic acids. The synthesis of arylglyoxylic amides have also been reported using Cu(II)-catalyzed^[@ref7],[@ref8]^ and tetrabutylammonium iodide-catalyzed reactions.^[@ref9]^ Therefore, the advent of a new coupling agent that could facilitate arylglyoxylic amide preparation could be an incremental advance in amide chemistry.

![Arylglyoxylic Amides](ao-2018-008945_0001){#sch1}

Previously, we demonstrated decarboxylative C- or N-acylation of arylglyoxylic acids under transition-metal-catalyzed or -free conditions.^[@ref10]^ During on-going investigation, we recently found that arylglyoxylic amides could be prepared from arylglyoxylic acids and *N*,*N*-dialkylamides in the presence of 2,3-dihalopyridines under palladium-catalyzed conditions. The crucial role of 2,3-dihalopyridines is proposed to be associated with the formation of vulnerable activated pyridyl ester of arylglyoxylic acid. The use of weak nucleophilic *N*,*N*-dialkylamides as amine surrogates appears to be essential for the formation of activated ester under the palladium-catalyzed condition. A premature mechanistic study reveals that the activated ester upon reaction with *N*,*N*-dialkylamides could deliver arylglyoxylic amides.

Results and Discussion {#sec2}
======================

Our initial investigation on palladium-catalyzed regioselective acylation of 2,3-dibromopyridine using arylglyoxylates in *N*,*N*-dimethylacetamide (DMA) via decarboxylation paved the way to the serendipitous synthesis of arylglyoxylic amides. Thus, heating the mixture of phenylglyoxylate **1a** and 2,3-dibromopyridine **A**~**1**~ in the presence of Pd(OAc)~2~, P(*o*-tol)~3~, and CuI in DMA **2a**, used as a solvent, gave arylglyoxylic amide **3a** unexpectedly ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Rather, the formation of 2,3-dibenzoylpyridine was the expected outcome. Exclusion of CuI gave a similar conversion to **3a** (entry 2). The yield was improved in the presence of a more electrophilic palladium-catalyst, Pd(TFA)~2~ (entry 3). Reducing the amount of **2a** in combination with the use of *N*-methyl-2-pyrrolidone (NMP) as solvent had an adverse effect (entry 4). A catalytic amount of 2,3-dibromopyridine had a detrimental effect (entries 5--6). Lowering the temperature was found to be ineffective (entries 7--8). The use of free acid in the presence of a base was not beneficial (entries 9--10). However, the use of (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO) as a radical quencher did not affect the yield of **3a** suggesting a nonradical pathway (entry 11). The product arylglyoxylic amide was not formed in the absence of palladium (entry 12).

###### Optimization Study[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-008945_0008){#GRAPHIC-d7e282-autogenerated}

  entry                                catalyst     ligand          temp/time (°C/h)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------------------------------------ ------------ --------------- ------------------ -------------------------------------------
  1[c](#t1fn3){ref-type="table-fn"}    Pd(OAc)~2~   P(*o*-Tol)~3~   150/24             55
  2                                    Pd(OAc)~2~   P(*o*-Tol)~3~   150/24             56
  3                                    Pd(TFA)~2~   P(*o*-Tol)~3~   150/24             71
  4[d](#t1fn4){ref-type="table-fn"}    Pd(TFA)~2~   P(*o*-Tol)~3~   150/24             25
  5[e](#t1fn5){ref-type="table-fn"}    Pd(OAc)~2~   P(*o*-Tol)~3~   150/24             42
  6[f](#t1fn6){ref-type="table-fn"}    Pd(OAc)~2~   P(*o*-Tol)~3~   150/24             29
  7                                    Pd(TFA)~2~   P(*o*-Tol)~3~   130/24             32
  8                                    Pd(TFA)~2~   P(*o*-Tol)~3~   100/24             00
  9[g](#t1fn7){ref-type="table-fn"}    Pd(TFA)~2~   P(*o*-Tol)~3~   150/24             00
  10[h](#t1fn8){ref-type="table-fn"}   Pd(TFA)~2~   P(*o*-Tol)~3~   150/24             32
  11[i](#t1fn9){ref-type="table-fn"}   Pd(TFA)~2~   P(*o*-Tol)~3~   150/24             69
  12                                                                150/24             00

Reaction conditions: **1a** (0.25 mmol), **2a** (1 mL), Pd-catalyst (5 mol %), ligand (10 mol %), 2,3-dibromopyridine **A**~**1**~ (1 equiv), 24 h.

Isolated yield.

CuI (15 mol %) used.

**2a** (2 equiv), NMP (1 mL) used.

**A**~**1**~ (0.5 equiv) used.

**A**~**1**~ (0.25 equiv) used.

Instead of **1a**, phenylglyoxylic acid (0.25 mmol) and K~2~CO~3~ (1 equiv) used.

Instead of **1a**, phenylglyoxylic acid (0.25 mmol) and KO*t*-Bu (1 equiv) used.

TEMPO (10 equiv) used.

We further explored the scope of other pyridine substrates that could help promote the formation of arylglyoxylic amides ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Similar to 2,3-dibromopyridine, 2,3-dichloropyridine **A**~**2**~ also produced **3a** in 64% yield under the reaction condition. While a mono-bromopyridine (2- or 3-bromopyridine) **A**~**3**~**--A**~**4**~ and its derivative **A**~**5**~ gave **3a** in varying yields along with the formation of their corresponding benzoylpyridines, mono-chloropyridine **A**~**6**~ failed to give **3a**. Likewise, pyridine itself or its derivative lacking any bromo-substituent **A**~**7**~**--A**~**13**~ failed to give **3a**. These substrates collectively unravel the requirement of mono-bromopyridines or 2,3-dihalopyridines as coupling additives for effective formation of **3a**. Interestingly, 1,2-dibromobenzene **A**~**14**~ did not give **3a** under the optimized condition.

![Additive Screening](ao-2018-008945_0002){#sch2}

Next, we explored the substrate scope of arylglyoxylates that could participate in the reaction ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). The arylglyoxylates containing both electron-rich and electron-poor substituents reacted with **2a** yielding arylglyoxylic amides **3b--3n** in good-to-excellent yields. The arylglyoxylates containing substituents at the 2-position afforded **3b--3c** in 79--84% yield. An arylglyoxylate containing an OMe group at the 3-position delivered **3d** in 78% yield. Furthermore, the arylglyoxylates bearing electron-donating groups at the 4-position afforded **3e--3h** in 62--81% yield. However, acids having electron-withdrawing groups at the 4-position yielded **3i--3j** in moderate yields. Interestingly, halogen groups that are otherwise often incompatible in metal-catalyzed reactions were tolerated to give **3k--3l** in 45--54% yield. Moreover, when 2-(naphthalen-2-yl)-2-oxoacetic acid was exposed to **2a**, the product **3m** was isolated in excellent (88%) yield. Heteroarylglyoxylic acids, 2-oxo-2-(thiophen-2-yl)acetic acid and 2-(furan-2-yl)-2-oxoacetic acid were also viable substrates giving **3n** and **3o**, respectively, in 61--66% yields.

![Substrate Scope of Arylglyoxylic Acids](ao-2018-008945_0003){#sch3}

To demonstrate further the greater synthetic potential of the protocol, different acyclic or cyclic acetamides were screened ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). It was found that when **1a** reacted with lower amount of **2a** (4 equiv) in the presence of mesitylene as solvent also gave **3a** in comparable (65%) yield. Other *N*,*N*-dialkylacetamide such as *N*,*N*-diethylacetamide **2b**, *N*,*N*-diisopropylacetamide **2c**, and *N*,*N*-dibenzylacetamide **2d** worked well affording **3p--3r** in 59--69% yields. Interestingly, cyclic acetamides were also found to be workable substrates. *N*-Acylpiperidines **2e--2f** reacted smoothly with **1a** to give the desired arylglyoxylic amide **3s** in excellent yields. Likewise, *N*-acetyl pyrrolidine **2g**, morpholine **2h**, and *N*-methyl piperazine **2i** were also viable substrates yielding **3t--3v** in 71--79% yields. Notably, *N*,*N*-dimethyl-2-phenylacetamide **2j** also worked under the reaction condition to give product **3a** in 78% yield. Similarly, *N*,*N*-dimethyl-2-(pyridin-2-yl)acetamide **2k** underwent reaction furnishing the product **3a** in moderate yield. However, *N*,*N*-dimethylbenzamide **2l** did not undergo the reaction under the optimized condition. Central to this investigation was the ability of various weak *N*,*N*-dialkylamides to serve as amino surrogates to form arylglyoxylic amides.

![Substrate Scope of Tertiary Alkylamides](ao-2018-008945_0004){#sch4}

To understand the possible pathway to the formation of **3a**, the identification of any putative intermediate that could form in this reaction and undergo subsequent reaction to form **3a** was sought ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). As benzoylpyridines were isolated as minor sideproducts when monobromopyrdines were used as additives (path A), we envisaged that benzoylpyridines could be the possible intermediates to the formation of **3a** ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). However, a control experiment involving the reaction of analytically pure 2-benzoylpyridine **3aa** under optimized condition did not afford **3a** (eq 1). Furthermore, *N*,*N*-dimethyl-2-(pyridin-2-yl)acetamide **3ab** could be a possible intermediate^[@ref11]^ in this reaction, which could be generated in the reaction of *N*,*N*-dialkylacetamide and 2-bromopyridine (path B). However, the attempted reaction of **3ab** and **1a** under the optimized condition did not give **3a** (eq 1). These two experiments precluded the formation arylglyoxylic amides from any putative intermediate proposed herein. Moreover, control experiments excluding either **2a** or **1a** performed under the optimized condition did not yield any isolable intermediate (eqs 2 and 3).

![Control Experiments](ao-2018-008945_0005){#sch5}

On the basis of the mechanistic information available with the cross-decarboxylative acylation of aryl halides using arylglyoxylic acids^[@ref12]^ and our own observations, we propose herein the following plausible reaction mechanism ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}). Initially, an oxidative addition of palladium(0) could occur at the 2-position of 2,3-dibromopyridine yielding **I**. However, palladium insertion at the 3-position of 2,3-dibromopyridine is not ruled out. Evidence for the formation of intermediate **I** warranted trapping the proposed intermediate. Thus, reaction of **1a** and **2a** under the standard condition in the presence of an additional amine, morpholine **2j** gave two aminated products of 2,3-dibromopyridine **3ac** and **3ad** as opposed to **3a** ([Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}). The regiochemistry of morpholine substitution in compound **3ac** is not known. It is important to note that only a limited data were obtained for compounds **3ac** and **3ad**. However, **3ac** and **3ad** were not formed in the absence of palladium and ligand. This rules out the possibility of SNAr reactions in this case.

![Plausible Reaction Mechanism](ao-2018-008945_0006){#sch6}

![Evidence for the Formation of Intermediate **I**](ao-2018-008945_0007){#sch7}

This experiment reveals that a strong nucleophile like morpholine **2j** could react with **I** to form **3ac** and **3ad**. However, in the absence of any other nucleophile, **1a** could react with the intermediate **I** to generate the intermediate **II**, which upon decarboxylation following a conventional pathway could form 2-benzoylpyridine. If decarboxylation is not facilitated under the condition, inadvertent reductive elimination of palladium(0) could occur with concomitant formation of the key pyridyl ester **III**. Amine nucleophile, which could be generated in situ from DMA in the presence of phenoxide **IV**, could react with the activated pyridyl ester **III** to deliver **3a**. While the proposed activated pyridyl ester of arylglyoxylic acid is unprecedented, the preparation of aryl carboxamides from pyridyl ester via activation to pyridinium salts^[@ref13]^ could be a reasonable evidence of the proof-of-concept. However, further study is required to confirm the hypothesis.

In conclusion, a palladium-catalyzed amidation of arylglyoxylic acids with *N*,*N*-dialkylamides in the presence of halopyridines has been developed. The salient features of this work may include (a) clear distinction from the previous reports of arylglyoxylic amide preparation, (b) use of weak nucleophilic *N*,*N*-dialkylamides as amino surrogates, and (c) novel activation of arylglyoxylic acids in the presence of halopyridines. Various other α-functionalized amides via activated pyridyl ester, their applications to the synthesis of pharmaceuticals, and detailed understanding of the mechanism could be a subject of intensive future research.

Experimental Section {#sec3}
====================

General {#sec3.1}
-------

Unless stated otherwise, all reagents and solvents were obtained from commercial sources and used as it is. All reactions were carried out in a screw capped tube. The ^1^H and ^13^C NMR spectra were obtained in CDCl~3~ as a solvent using a 400 MHz spectrometer with tetramethylsilane as an internal standard. Coupling constants (*J* values) are described in Hz. Silica gel (60--120\#, 100--200\#, and 230--400\#) was used to perform column chromatography. High-resolution mass spectra (HRMS) were obtained by the use of electron spray ionization and time-of-flight mass analyzer. IR spectra are stated in cm^--1^ units.

Preparation of Substituted α-Oxocarboxylic Acids (**1b--1n**) {#sec3.2}
-------------------------------------------------------------

All substituted α-oxocarboxylic acids were prepared using the literature protocol.^[@ref14]^

General Procedure for the Synthesis of Potassium Salts of the α-Oxocarboxylic Acids (**1a--1n**) {#sec3.3}
------------------------------------------------------------------------------------------------

Following a literature procedure,^[@ref15]^ a solution of potassium *tert*-butoxide (1 mmol) in ethanol (1 mL) was added drop-by-drop to a solution of α-oxocarboxylic acids (1 mmol) in ethanol (1 mL) over 30 min. After complete addition, the reaction mixture was stirred for another 2 h at room temperature. A gradual formation of a precipitate was observed. The resulting solid was collected by filtration, washed with ethanol (2 × 10.0 mL) and diethyl ether (10.0 mL), transferred to a round-bottom flask, and dried under vacuum to give corresponding potassium salts of α-oxocarboxylic acids.^[@ref2]^

General Procedure for the Synthesis of α-Ketoamides (**3a--3o**) {#sec3.4}
----------------------------------------------------------------

A reaction tube was charged with α-oxocarboxylic acid (0.25 mmol), 2,3-dibromo pyridine (1 equiv), Pd(TFA)~2~ (5 mol %), and P(*o*-Tol)~3~ (10 mol %). The tube was evacuated and backfilled with nitrogen. DMA (1 mL) was added by syringe under flow of nitrogen. The tube was sealed and the mixture was heated at 150 °C for 24 h. The reaction mixture was cooled down to room temperature, and the residue was diluted with ethyl acetate (10 mL), washed with saturated sodium carbonate solution (10 mL), and extracted with EtOAc (20 mL × 2). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography \[100--200\# silica, ethyl acetate/hexane = 3:7/4:6\] to afford the desired α-ketoamides product.

General Procedure for the Synthesis of α-Ketoamides Using *N*,*N*-Dialkyacetamides ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}: **3a**, **3p--3v**) {#sec3.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A reaction tube was charged with α-oxocarboxylic acid (0.25 mmol), *N*,*N*-dialkylacetamide (4 equiv), 2,3-dibromo pyridine (1 equiv), Pd(TFA)~2~ (5 mol %), and P(*o*-Tol)~3~ (10 mol %). The tube was evacuated and backfilled with nitrogen. Mesitylene (1 mL) was added by syringe under flow of nitrogen. The tube was sealed and the mixture was heated at 150 °C for 24 h. The reaction mixture was cooled down to room temperature, and the residue was diluted with ethyl acetate (10 mL), washed with saturated sodium carbonate solution (10 mL), and extracted with EtOAc (20 mL × 2). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography \[100--200\# silica, ethyl acetate/hexane = 3:7/4:6\] to afford the desired α-ketoamides product.

Typical Procedure for the Competitive Experiment {#sec3.6}
------------------------------------------------

A reaction tube was charged with α-oxocarboxylic acid (0.25 mmol), DMA (4 equiv), morpholine (4 equiv), 2,3-dibromo pyridine (1 equiv), Pd(TFA)~2~ (5 mol %), and P(*o*-Tol)~3~ (10 mol %). The tube was evacuated and backfilled with nitrogen. Mesitylene (1 mL) was added by syringe under flow of nitrogen. The tube was sealed and the mixture was heated at 150 °C for 24 h. The reaction mixture was cooled down to room temperature, and the residue was diluted with ethyl acetate (10 mL), washed with saturated sodium carbonate solution (10 mL), and extracted with EtOAc (20 mL × 2). The combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified through column chromatography \[100--200\# silica, ethyl acetate/hexane = 1:9\] to give the C--H aminated products.

Characterization of Synthesized Compounds {#sec3.7}
-----------------------------------------

### *N*,*N*-Dimethyl-2-oxo-2-phenylacetamide (**3a**)^[@ref7]^ {#sec3.7.1}

Yellow oil; yield 71% (30 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.95 (d, *J* = 7.9 Hz, 2H), 7.65 (tt, *J* = 7.4, 1.1 Hz, 1H), 7.51 (t, *J* = 7.8 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.8, 167.0, 134.7, 133.0, 129.6, 129.0, 37.0, 34.0.

### *N*,*N*-Dimethyl-2-oxo-2-(*o*-tolyl)acetamide (**3b**)^[@ref7]^ {#sec3.7.2}

Yellow oil; yield 84% (40 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.70 (d, *J* = 7.8 Hz, 1H), 7.49 (t, *J* = 7.3 Hz, 1H), 7.34--7.31 (m, 2H), 3.12 (s, 3H), 2.99 (s, 3H), 2.67 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 193.7, 167.8, 141.4, 133.6, 132.5, 131.6, 126.1, 37.0, 34.0, 21.6.

### 2-(2-Ethoxyphenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3c**) {#sec3.7.3}

Yellow oil; yield 79% (43 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.95 (dd, *J* = 7.8, 1.8 Hz, 1H), 7.55 (td, *J* = 7.3, 1.8 Hz, 1H), 7.07 (td, *J* = 7.9, 0.8 Hz, 1H), 6.96 (d, *J* = 8.3 Hz, 1H), 4.11 (q, *J* = 6.9 Hz, 2H), 3.06 (s, 3H), 2.99 (s, 3H), 1.41 (t, *J* = 6.9 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.9, 168.8, 159.6, 135.9, 131.0, 123.4, 121.0, 112.5, 64.2, 36.8, 33.8; HRMS: calcd for C~12~H~16~NO~3~ \[M + H\]^+^, 222.1130; found, 222.1138; IR (KBr): 1675, 1648, 1436, 1210, 1144 cm^--1^.

### 2-(3-Methoxyphenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3d**)^[@ref8]^ {#sec3.7.4}

Yellow oil; yield 78% (40 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.51--7.44 (m, 2H), 7.42 (t, *J* = 7.3 Hz, 1H), 7.22--7.19 (m, 1H), 3.88 (s, 3H), 3.13 (s, 3H), 2.97 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.6, 167.0, 160.1, 134.4, 130.0, 122.8, 121.6, 112.7, 55.5, 37.0, 34.0.

### *N*,*N*-Dimethyl-2-oxo-2-(*p*-tolyl)acetamide (**3e**)^[@ref9]^ {#sec3.7.5}

Yellow oil; yield 64% (30 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.85 (d, *J* = 8.2 Hz, 2H), 7.32 (d, *J* = 7.9 Hz, 2H), 3.12 (s, 3H), 2.96 (s, 3H), 2.44 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.5, 167.2, 145.9, 130.6, 129.7, 129.7, 37.0, 33.9, 21.8.

### 2-(4-Methoxyphenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3f**)^[@ref9]^ {#sec3.7.6}

Yellow oil; yield 62% (32 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.93 (d, *J* = 8.8 Hz, 2H), 6.99 (d, *J* = 8.8 Hz, 2H), 3.90 (s, 3H), 3.12 (s, 3H), 2.97 (s, 3H).

### 2-(4-Ethoxyphenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3g**) {#sec3.7.7}

Yellow oil; yield 67% (37 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.91 (d, *J* = 7.0 Hz, 2H), 6.96 (d, *J* = 8.8 Hz, 2H), 4.12 (q, *J* = 7.0 Hz, 2H), 3.11 (s, 3H), 2.97 (s, 3H), 1.46 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.5, 167.4, 164.3, 132.1, 125.9, 114.7, 64.00, 37.1, 33.9, 14.6; HRMS: calcd for C~12~H~16~NO~3~ \[M + H\]^+^, 222.1130; found, 222.1135; IR (KBr): 1679, 1650, 1444, 1132 cm^--1^.

### *N*,*N*-Dimethyl-2-oxo-2-(4-(trifluoromethoxy)phenyl)acetamide (**3h**) {#sec3.7.8}

Yellow oil; yield 81% (53 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.04 (d, *J* = 8.8 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 3.14 (s, 3H), 3.00 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 189.9, 166.4, 153.7, 131.8, 131.2, 130.0, 128.5, 121.5, 120.6, 118.9; HRMS: calcd for C~11~H~11~F~3~NO~3~ \[M + H\]^+^, 262.0691; found, 262.0699; IR (KBr): 1680, 1647, 1432, 1140 cm^--1^.

### 2-(4-Cyanophenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3i**) {#sec3.7.9}

Yellow oil; yield 47% (24 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.72 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 3.13 (s, 3H), 2.96 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 169.5, 140.6, 132.3, 127.7, 118.1, 113.3, 39.3, 35.3; HRMS: calcd for C~11~H~11~N~2~O~2~ \[M + H\]^+^, 203.0821; found, 203.0831; IR (KBr): 2237, 1683, 1645, 1442, 1218, 1136 cm^--1^.

### *N*,*N*-Dimethyl-2-(4-nitrophenyl)-2-oxoacetamide (**3j**)^[@ref9]^ {#sec3.7.10}

Yellow solid; yield 57% (31 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.27 (dd, *J* = 6.8, 1.8 Hz, 2H), 7.58 (dd, *J* = 6.8, 1.9 Hz, 2H), 3.14 (s, 3H), 2.96 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 169.2, 148.3, 142.4, 128.0, 123.8, 39.3, 35.3.

### 2-(4-Chlorophenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3k**)^[@ref9]^ {#sec3.7.11}

Yellow oil; yield 54% (28 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.86 (d, *J* = 8.4 Hz, 2H), 7.46 (d, *J* = 8.5 Hz, 2H), 3.08 (s, 3H), 2.93 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.3, 166.4, 141.3, 131.4, 131.0, 129.3, 37.0, 34.0.

### 2-(4-Fluorophenyl)-*N*,*N*-dimethyl-2-oxoacetamide (**3l**)^[@ref9]^ {#sec3.7.12}

White solid; yield 45% (22 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.03--7.99 (m, 2H), 7.22--7.18 (m, 2H), 3.14 (s, 3H), 2.99 (s, 3H).

### *N*,*N*-Dimethyl-2-(naphthalen-2-yl)-2-oxoacetamide (**3m**)^[@ref7]^ {#sec3.7.13}

Yellow solid; yield 88% (50 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.46 (s, 1H), 8.05 (dd, *J* = 8.6, 1.7 Hz, 1H), 8.01--7.95 (m, 2H), 7.92 (d, *J* = 7.1 Hz, 1H), 7.67 (td, *J* = 7.0, 1.2 Hz, 1H), 7.59 (td, *J* = 8.1, 1.1 Hz), 3.20 (s, 3H), 3.02 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.8, 167.1, 136.3, 133.0, 132.4, 130.4, 129.9, 129.3, 129.0, 127.9, 127.1, 123.6, 37.1, 34.1.

### *N*,*N*-Dimethyl-2-oxo-2-(thiophen-2-yl)acetamide (**3n**)^[@ref7]^ {#sec3.7.14}

Yellow oil; yield 61% (29 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.79--7.74 (m, 1H), 7.72--7.71 (m, 1H), 7.12--7.10 (m, 1H), 3.03 (s, 3H), 2.97 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 183.4, 165.8, 140.3, 136.3, 136.1, 128.6, 37.3, 34.5.

### 2-(Furan-2-yl)-*N*,*N*-dimethyl-2-oxoacetamide (**3o**)^[@ref7]^ {#sec3.7.15}

Yellow oil; yield 66% (28 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.72 (d, *J* = 1.0 Hz, 1H), 7.37 (d, *J* = 3.7 Hz, 1H), 6.62--6.60 (m, 1H), 3.08 (s, 3H), 3.03 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 178.5, 165.4, 150.1, 148.7, 37.2, 34.5.

### *N*,*N*-Diethyl-2-oxo-2-phenylacetamide (**3p**)^[@ref9]^ {#sec3.7.16}

Yellow oil; yield 62% (31 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.94 (d, *J* = 8.4 Hz, 2H), 7.65--7.61 (m, 1H), 7.51 (t, *J* = 7.7 Hz, 1H), 3.56 (q, *J* = 7.2 Hz, 2H), 3.24 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.2 Hz, 3H), 1.16 (t, *J* = 7.1 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.6, 166.7, 134.5, 133.2, 129.6, 128.9, 42.1, 38.8, 14.1, 12.8.

### *N*,*N*-Diisopropyl-2-oxo-2-phenylacetamide (**3q**)^[@ref16]^ {#sec3.7.17}

Colorless solid; yield 69% (40 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.95 (d, *J* = 7.3 Hz, 2H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 2H), 3.70 (q, *J* = 6.8 Hz, 1H), 3.60 (q, *J* = 6.8 Hz, 1H), 1.60 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.6 Hz, 6H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.0, 166.9, 134.4, 133.3, 129.5, 128.9, 50.2, 46.0, 20.5, 20.3.

### *N*,*N*-Dibenzyl-2-oxo-2-phenylacetamide (**3r**)^[@ref17]^ {#sec3.7.18}

Yellow oil; yield 57% (47 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.02 (d, *J* = 7.8 Hz, 2H), 7.67 (t, *J* = 7.4 Hz, 1H), 7.54 (t, *J* = 7.8 Hz, 2H), 7.44--7.42 (m, 2H), 7.41--7.32 (m, 6H), 7.28--7.26 (m, 2H), 4.65 (s, 2H), 4.30 (s, 2H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.3, 167.4, 135.9, 134.8, 134.7, 134.5, 133.2, 131.2, 129.7, 129.0, 128.9, 128.8, 128.7, 128.5, 128.2, 128.1, 127.9, 127.8, 50.0, 46.0.

### 1-Phenyl-2-(piperidin-1-yl)ethane-1,2-dione (**3s**)^[@ref9]^ {#sec3.7.19}

Yellow oil; yield 83% (45 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.96 (d, *J* = 8.4 Hz, 2H), 7.66 (t, *J* = 7.4 Hz, 1H), 7.53 (d, *J* = 7.8 Hz, 2H), 3.72 (br s, 2H), 3.31 (t, *J* = 5.5 Hz, 2H), 1.72--1.67 (m, 4H), 1.58--1.51 (m, 2H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.9, 165.4, 134.6, 133.2, 129.5, 129.0, 128.4, 47.0, 42.1, 26.2, 25.4, 24.3.

### 1-Phenyl-2-(pyrrolidin-1-yl)ethane-1,2-dione (**3t**)^[@ref18]^ {#sec3.7.20}

Yellow oil; yield 71% (36 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.00 (d, *J* = 8.5 Hz, 2H), 7.65 (tt, *J* = 7.4, 1.2 Hz, 1H), 7.52 (t, *J* = 7.8 Hz, 2H), 3.68 (t, *J* = 6.9 Hz, 2H), 3.45 (t, *J* = 6.2 Hz, 2H), 2.00--1.94 (m, 4H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.5, 164.9, 134.6, 132.9, 129.9, 128.9, 46.6, 45.2, 25.9, 24.0.

### 1-Morpholino-2-phenylethane-1,2-dione (**3u**)^[@ref9]^ {#sec3.7.21}

Yellow oil; yield 74% (40 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.96 (d, *J* = 8.5 Hz, 2H), 7.66 (tt, *J* = 7.4 Hz, 1H), 7.52 (t, *J* = 7.9 Hz, 2H), 3.80 (s, 4H), 3.66 (t, *J* = 4.7 Hz, 2H), 3.38 (t, *J* = 5.5 Hz, 2H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.1, 165.4, 134.9, 133.0, 129.6, 129.1, 66.7, 66.6, 46.2, 41.6.

### 1-(4-Methylpiperazin-1-yl)-2-phenylethane-1,2-dione (**3v**)^[@ref18]^ {#sec3.7.22}

Yield 79% (46 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 7.96 (d, *J* = 7.4 Hz, 2H), 7.66 (t, *J* = 7.4 Hz, 1H), 7.53 (d, *J* = 7.8 Hz, 2H), 3.82 (t, *J* = 4.8 Hz, 2H), 3.40 (t, *J* = 4.8 Hz, 2H), 2.55 (t, *J* = 5.1 Hz, 2H), 2.41 (t, *J* = 5.0 Hz, 2H), 2.34 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.4, 165.3, 134.8, 133.0, 129.6, 129.0, 54.8, 54.4, 45.9, 45.7, 41.0.

### Phenyl(pyridin-2-yl)methanone (**3aa**)^[@ref19]^ {#sec3.7.23}

Yellow oil; ^1^H NMR (400 MHz, CDCl~3~): δ 8.72 (d, *J* = 4.7 Hz, 1H), 8.07--8.03 (m, 3H), 7.90 (td, *J* = 7.7, 1.6 Hz, 1H), 7.61--7.57 (m, 1H), 7.50--7.47 (m, 3H).

### 4-(2- or 3-Bromopyridin-2-yl)morpholine (**3ac**) {#sec3.7.24}

Yellow oil; yield 35% (21 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.25 (dd, *J* = 4.7, 1.4 Hz, 1H), 7.80 (dd, *J* = 7.7, 1.5 Hz, 1H), 6.82--6.79 (m, 1H), 3.88 (t, *J* = 4.6 Hz, 4H), 3.35 (t, *J* = 4.6 Hz, 4H). (Note only a limited data obtained for the mixture).

### 4-(Pyridin-2-yl)morpholine (**3ad**) {#sec3.7.25}

Yellow oil; yield 35% (14 mg); ^1^H NMR (400 MHz, CDCl~3~): δ 8.22 (d, *J* = 3.7 Hz, 1H), 7.52 (dt, *J* = 8.7, 1.9 Hz, 1H), 6.70--6.65 (m, 2H), 3.85 (t, *J* = 4.7 Hz, 4H), 3.51 (t, *J* = 4.7 Hz, 4H). (Note only a limited data obtained for the compound).
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